Evidence map›Paper›PMID 35246243›Full record

Trial reportBMC research notes2022

The glucose-lowering effect of low-dose diacerein and its responsiveness metabolic markers in uncontrolled diabetes.

Jintanan Jangsiripornpakorn, Sasima Srisuk, Laor Chailurkit, Hataikarn Nimitphong, Sunee Saetung, Boonsong Ongphiphadhanakul

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC research notes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06912035 (EFFICACY OF DIACEREIN ADDITION ON INTERLEUKIN-1Β, HS-CRP, TNF-Α LEVELS AND GLYCEMIC CONTROL IN UNCONTROLLED TYPE 2 DIABETES MELLITUS PATIENTS AT DR. MOHAMMAD HOESIN GENERAL HOSPITAL PALEMBANG), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06912035 phase2 / phase3completednot on this mapstarted 2024, after this paper: background citation

Efficacy of diacerein addition on interleukin-1β, hs-crp, tnf-α levels and glycemic control in uncontrolled type 2 diabetes mellitus patients at dr. mohammad hoesin general hospital palembang

TypeinterventionalSponsorUniversitas SriwijayaRan2024 to 2024Enrolled34ConditionsUncontrolled Diabetes, Diabetes Mellitus Type 2ArmsDiacerein 50 mg Capsule, Placebo
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Inflammation and resolution in obesity.Nature reviews. Endocrinology · 2025 · on this map
    Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Jintanan JangsiripornpakornTaksin Hospital, Bangkok, Thailand.
Sasima SrisukBangkok Metropolitan Administration General Hospital, Bangkok, Thailand.
Laor ChailurkitFaculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Hataikarn NimitphongFaculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Sunee SaetungFaculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Boonsong OngphiphadhanakulFaculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. boonsong.ong@mahidol.ac.th.
Mahidol University · THRamathibodi Hospital · THBangkok Metropolitan Administration · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveDiacerein inhibits the synthesis and activity of pro-inflammatory cytokines, decreases macrophage infiltration in adipose tissue and thus increases insulin sensitivity and signalling. We conducted this study to determine the efficacy of low-dose diacerein in improving glycaemic control in type 2 diabetes mellitus (T2DM) patients with inadequate glycaemic control and to identify the metabolic determinants for such improvement. We randomised 25 T2DM patients with poor glycaemic control, despite being treated with at least three glucose-lowering agents, to receive diacerein 50 mg once-daily (n = 18) or placebo (n = 17) for 12 weeks. Changes in glycated haemoglobin (HbA1c) were evaluated at the 4th and 12th weeks. Metabolic profiling was performed using liquid chromatography electrospray ionisation quadrupole time-of-flight mass spectrometry.

resultsHbA1c levels were significantly reduced from baseline in the diacerein group at 12 weeks (- 0.6%, p < 0.05), whereas fasting plasma glucose (FPG) levels were not significantly decreased (- 18.9 mg/dl, p = 0.06). Partial least squares-discriminant analysis demonstrated an association between the serum abundance of threo-isocitric acid (ICA) and HbA1c response in the diacerein group. After adjusting for serum high-sensitivity C-reactive protein, ICA was still significantly related to the change in HbA1c. Retrospective trial registration Current Controlled Trials TCTR20200820004, 20 August 2020.

Indexed as

Diabetes Mellitus, Type 2AnthraquinonesBlood GlucoseDouble-Blind MethodGlycated HemoglobinHumansHypoglycemic AgentsRetrospective StudiesTreatment OutcomeAnthraquinonesBlood GlucosediacereinGlycated HemoglobinHypoglycemic AgentsDiacereinGlycemic controlInflammationMetabolomicsType 2 diabetes

Identifiers

PMID35246243
PMCPMC8896078
OpenAlexW4214911085

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.